Genentech

#Breaking: Today meaningful data from our Phase III study in systemic lupus erythematosus was published in @NEJM. Learn more: gene.com/media/press-re…

#Breaking: Positive Phase II results for our investigational long‑acting amylin analog with Zealand Pharma mark an important step forward as we move from a one‑size‑fits‑all approach to more tailored options for people living with #obesity. gene.com/media/press-re…

#Breaking: Today we announced positive additional Phase III clinical results of our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-re…

#Breaking: @US_FDA approved our new combination regimen as the first and only all-oral, fixed-duration treatment for previously untreated adults with chronic lymphocytic leukemia (CLL). Learn more: gene.com/media/press-re…

#Breaking: @US_FDA accepts New Drug Application for our investigational oral therapy in ER+ advanced #BreastCancer. Learn more: gene.com/media/press-re…

#Breaking: Today we announced positive Phase III data in primary membranous nephropathy. Learn more: gene.com/media/press-re…

#Breaking: At the #ACTRIMSForum, we revealed the full results from our Phase III clinical study of our investigational BTK inhibitor (BTKi) in primary progressive multiple sclerosis (PPMS). Read more: gene.com/media/press-re…

#Breaking: Today we announced positive Phase II results for our dual GLP-1/GIP receptor agonist for people living with #obesity. Learn more: gene.com/media/press-re…

#Breaking: Today, we announced an expansion of our investment in Holly Springs, NC, to approximately $2B. This investment supports the production of next-generation medicines for metabolic disorders, including obesity. We’re proud to be part of North Carolina’s growing biotech ecosystem. gene.com/media/press-re…

#Breaking: The @US_FDA approved our new subcutaneous formulation for the treatment of third-line or later relapsed or refractory follicular lymphoma (FL). Learn more about how we’re developing patient-centered solutions: gene.com/media/press-re…

#Breaking: At #SABCS25, we’re presenting transformational data from our positive Phase III study for people with ER+, HER2-, early-stage breast cancer. Learn more: gene.com/media/press-re…

#Breaking: Data at #ASH25 highlights the potential of our combination therapy in earlier lines for hard-to-treat blood cancers. Learn more: gene.com/media/press-re…

#Breaking: New Phase III trial data show significant improvement in invasive disease-free survival for ER+, HER2- early-stage #BreastCancer. Learn more: gene.com/media/press-re…

#Breaking: Today we announced positive Phase III clinical results of our investigational BTK inhibitor in primary progressive multiple sclerosis (PPMS) and relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-re…

#Breaking: At #ASH25, we’re presenting data across our #hematology portfolio, reinforcing our commitment to addressing remaining unmet needs for people living with hemophilia A, lymphoma and multiple myeloma. Explore our latest research: gene.com/media/press-re…

#Breaking: New positive Phase III data for patients with systemic lupus erythematosus. Learn more: gene.com/media/press-re…

#Breaking: Today we announced positive results from our Phase III study in idiopathic nephrotic syndrome (INS). Learn more: gene.com/media/press-re…

ICYMI: Our medicine to treat lupus nephritis in adults was granted approval by the @US_FDA. Learn more: spr.ly/6019A4AYx

ICYMI: At #ESMO25, our Phase III study showed an investigational, all-oral estrogen blocker combination improved progression-free survival in advanced ER+ breast cancer. Learn more: spr.ly/6016AAnmp

#Breaking: We’re presenting Phase III data showing improved outcomes in muscle-invasive bladder cancer (#MIBC) at #ESMO25. Learn more: gene.com/media/press-re…